Adverse Interactions Between Warfarin and Nonsteroidal Antiinflammatory Drugs: Mechanisms, Clinical Significance, and Avoidance
- 1 December 1995
- journal article
- review article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 29 (12) , 1274-1283
- https://doi.org/10.1177/106002809502901214
Abstract
Objective: To review the mechanisms and clinical significance of adverse interactions between warfarin and nonsteroidal antiinflammatory drugs (NSAIDs) and discuss how these interactions can be avoided. Data Sources: Previous studies of interactions between warfarin and NSAIDs or reports of adverse interactions were identified from a MEDLINE search (1976 to present) and from the reference lists of pertinent articles. Study Selection And Data Extraction: All articles were considered for inclusion in the review. Pertinent information was selected for discussion. Data Synthesis: All NSAIDs can prolong bleeding time by inhibiting platelet function. High-dose aspirin has a direct hypoprothrombinemic effect. Phenylbutazone and its analogs enhance the hypoprothrombinemic effect of warfarin through a pharmacokinetic interaction by inhibiting the hepatic metabolism of warfarin. Mefenamic acid also enhances the anticoagulant effect of warfarin, but the mechanism is not known. The clinical relevance of protein binding displacement in the interaction between warfarin and NSAIDs has been overstated, although a significant one may be more likely in the presence of high concentrations of NSAIDs in patients with slow elimination of warfarin (e.g., those with severe heart failure or impaired liver function). NSAIDs can induce gastrointestinal bleeding, which is likely to be more severe if warfarin is also given. Conclusions: The combined use of warfarin and NSAIDs is generally discouraged because of the increased risk of bleeding in these patients. In patients receiving warfarin who also require NSAIDs, phenylbutazone and its analogs, high-dose aspirin, mefenamic acid, excessive use of topical methyl salicylate, and NSAIDs that are associated with a higher risk of bleeding peptic ulcers should be avoided. Patients should be closely monitored for anticoagulant control and bleeding complications during the combined use of warfarin and NSAIDs.Keywords
This publication has 76 references indexed in Scilit:
- Clinically Significant Drug Interactions with the Oral AnticoagulantsDrug Safety, 1994
- Adverse Interaction between Warfarin and IndomethacinDrug Safety, 1994
- Adverse Drug Interactions with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)Drug Safety, 1993
- Adverse Reactions to Drugs as a Cause of Admissions to a General Teaching Hospital in Hong KongDrug Safety, 1992
- Protein Binding Drug Displacement InteractionsClinical Pharmacokinetics, 1989
- Clinical Pharmacokinetics and Pharmacodynamics of WarfarinClinical Pharmacokinetics, 1986
- Drug Interactions with WarfarinDrugs, 1983
- Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man.Circulation, 1982
- Interaction Between Sulindac and Warfarin: Different Results in Normal Subjects and in an Unusual Patient with a Potassium‐Losing Renal Tubular DefectThe Journal of Clinical Pharmacology, 1979
- Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in manJournal of Pharmacy and Pharmacology, 1973